News in Numbers

The value GLP-1 receptor agonist sales are expected to reach by 2033.

The total value of partnership deals for metabolic dysfunction-associated steatohepatitis (MASH) innovator drugs forged in Q1 2024 is around $2bn.

Moderna reported a net revenue loss of $1.2bn in its Q4 2024 financial report.

The US wholesale acquisition cost (WAC) for a one-time treatment of Lenmeldy, a gene therapy for metachromatic leukodystrophy (MLD), will be $4.25m.

Drugmaker Sanofi has made a $1.07bn investment into expanding biomanufacturing capacities at its sites in France.